ReviewCell biochemistry and biophysics2026
Necrosis by Sodium Overload: Mechanisms, Pathophysiological Roles, and Therapeutic Prospects of a Novel Form of Regulated Cell Death.
Review in Cell biochemistry and biophysics, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Sodium ion (Na⁺), the predominant cation in the extracellular space, is essential for maintaining fundamental cellular activities via preservation of the transmembrane Na⁺ gradient. While intracellular Ca²⁺ overload has long been recognized as the core driver of cell injury and death, accumulating evidence indicates that Na⁺ overload, defined as abnormal intracellular Na⁺ accumulation, may act as an independent trigger of irreversible cellular damage, rather than merely a preceding event or concomitant phenomenon of Ca²⁺ overload. In 2025, the term Necrosis by Na⁺ Overload (NECSO) was first coined to describe a novel form of regulated necrosis directly triggered by sustained and excessive Na⁺ influx, which is primarily mediated by the transient receptor potential melastatin 4 (TRPM4) channel. Distinct from apoptosis and other established forms of regulated cell death, NECSO is characterized by early cellular and organellar swelling, mitochondrial energy metabolism collapse, ionic homeostasis disruption, and eventual loss of plasma membrane integrity, without the hallmark features of caspase activation and chromatin condensation. The core execution pathway of NECSO involves TRPM4-mediated Na⁺ influx, subsequent mitochondrial Na⁺ accumulation, impaired tricarboxylic acid cycle and oxidative phosphorylation, and catastrophic cellular energy depletion, which further aggravates Na⁺ overload via inhibition of Na⁺/K⁺-ATPase and forms a fatal vicious cycle. In pathophysiological contexts, NECSO serves as a central mediator of myocardial injury in ischemia-reperfusion, and is also implicated in the progression of heart failure and neuronal death in stroke. In cancer biology, NECSO and its core mediator TRPM4 exhibit highly tissue-specific dual roles, acting as either oncogenic drivers or tumor suppressors in different cancer types. Meanwhile, NECSO-related genes have shown promising potential as diagnostic and prognostic biomarkers, as well as predictors of therapeutic response to chemotherapy and immunotherapy across multiple malignancies. Targeted strategies against NECSO, including direct modulation of TRPM4 activity, intervention of Na⁺ homeostasis, and combination therapeutic regimens, have exhibited favorable efficacy in preclinical models of cardiovascular diseases and cancer. This review systematically summarizes the definition, core molecular mechanisms, and pathophysiological functions of NECSO, discusses the application value of NECSO-related biomarkers, and outlines current challenges and future directions in this emerging field, to provide a novel perspective for the development of therapeutic strategies against major human diseases.
Indexed as
Identifiers
42709394What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.